Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Final Results

3 May 2006 10:34

ISIS Resources PLC03 May 2006 ISIS RESOURCES PLC ("Isis" or the "Company") Final results for the period ended 31 December 2005 Chairman's statement The Company was incorporated on 24 February 2005 and its ordinary shares wereadmitted to AIM on 31 March 2005 in conjunction with a fundraising ofapproximately £1 million. During the period since admission to AIM, the Directors have reviewed a numberof natural resource opportunities and, in each case, concluded that theproposition did not offer an appropriate level of return for the risk to beassumed. Consequently, the Directors reviewed the Company's investment strategyand widened the range of potential investments. On 31 March 2006, the Directors announced that the company's shares had beensuspended from trading on AIM in accordance with the Guidance Note to Rule 8 ofthe AIM Rules. The Directors further announced that they are in discussions inrelation to the acquisition of a drug discovery company which is focused on thediscovery and development of new therapeutic drugs for the treatment of rhinitisand other chronic respiratory and inflammatory diseases. The acquisition wouldbe classified as a reverse takeover under the AIM Rules and, as such, would besubject to the approval of shareholders. In conjunction with the acquisition, the Directors announced that the Companyintends to undertake a placing of ordinary shares through its nominated adviserand broker, Westhouse Securities LLP. The Directors expect that an AIMadmission document in connection with the acquisition will be published aroundthe end of May 2006. Craig Burton Executive Chairman Contact Details: Craig Burton 00 61 8 9324 1177 Isis Resources Plc Tim Feather 020 7601 6100 Westhouse Securities LLP INCOME STATEMENT FOR THE PERIOD ENDED 31 DECEMBER 2005 Notes £ Revenue - Cost of sales - __________Gross profit - Administration expenses (11,380) Other operating income 3,899 __________ Operating profit/(loss) (7,481) Investment income 33,448 __________ Profit before taxation 25,967 Taxation - __________ Profit for the period 25,967 ========= Earnings per ordinary share 1 0.06p __________ Diluted earnings per ordinary share 1 0.05p __________ BALANCE SHEET AS AT 31 DECEMBER 2005 £ ASSETS Current assets Trade and other receivables 8,918 Cash and cash equivalents 982,408 __________ 991,326 __________ Total assets 991,326 ========= EQUITY AND LIABILITIES Share capital 50,200 Share premium account 903,412 Retained losses 25,967 __________ Total equity 979,579 __________ Current liabilities Trade and other payables 11,747 __________ Total liabilities 11,747 __________ Total equity and liabilities 991,326 ========= CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 DECEMBER 2005 £ Net cash inflows from operating activities 2,173 __________ Investing activities Interest received 26,623 __________ 26,623 __________ Financing activities Net proceeds from issue of ordinary share capital 953,612 __________ 953,612 __________ Net increase in cash and cash equivalents 982,408 Cash and cash equivalents at the beginning of the period - __________ Cash and cash equivalents at the end of the period 982,408 ========= Notes to the preliminary results for the period ended 31 December 2005 1. Earnings per share Basic earnings per share of 0.06p is calculated by dividing the profit for theperiod by the weighted average number of ordinary shares in issue of 44,754,194. Diluted earnings per share of 0.05p is calculated by dividing the profit for theperiod by the diluted weighted average number of ordinary shares of 54,611,613,being the number of ordinary shares in issue and allowing for the exercise ofoptions outstanding. 2. Publication of non-statutory accounts The financial information set out in this preliminary announcement does notconstitute statutory accounts as defined in section 240 of the Companies Act1985. The summarised consolidated balance sheet at 31 December 2005 and thesummarised consolidated profit and loss account, summarised consolidatedcashflow statement and associated notes for the year then ended have beenextracted from the Group's 2005 statutory financial statements upon which theauditors' opinion is unqualified and does not contain any statement undersection 237 of the Companies Act 1985. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
28th Oct 202011:01 amGNWVerona Pharma plc : Update on AIM Delisting
23rd Oct 20205:30 pmRNSVerona Pharma
22nd Oct 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
13th Oct 20207:00 amGNWVerona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
23rd Sep 20209:06 amGNWVerona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
21st Sep 20207:00 amGNWIntended Delisting and Cancellation of Ordinary Shares from Trading on AIM
17th Sep 20207:00 amGNWVerona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
16th Sep 20201:25 pmGNWVerona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
8th Sep 20207:00 amGNWVerona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
2nd Sep 20207:00 amGNWVerona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
26th Aug 202010:19 amGNWVerona Pharma plc: Grant of RADSUs and PDMR Dealings
24th Aug 20207:00 amGNWVerona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
19th Aug 20207:00 amGNWVerona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
7th Aug 20203:46 pmGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
4th Aug 20206:13 pmGNWVerona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights
3rd Aug 20207:00 amGNWVerona Pharma Announces August 2020 Virtual Investor Conference Participation
30th Jul 202010:52 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
30th Jul 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
27th Jul 20207:01 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
22nd Jul 20204:50 pmGNWClosing of Financing, Issued Share Capital and Total Voting Rights
17th Jul 20205:47 pmGNWVerona Pharma plc: PDMR Dealings
17th Jul 20207:00 amGNWVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
6th Jul 20204:04 pmGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
14th May 20207:00 amGNWVerona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
12th May 20201:11 pmGNWDirector/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
1st May 20205:12 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
30th Apr 20207:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
23rd Apr 20207:00 amGNWVerona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
16th Apr 202012:12 pmGNWVerona Pharma plc: Results of AGM
8th Apr 20207:00 amGNWUpdate on AGM Procedure
31st Mar 20207:00 amGNWVerona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
20th Mar 202011:28 amGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:01 pmRNSPrice Monitoring Extension
16th Mar 20205:13 pmGNW2019 Annual Report and Accounts and Notice of AGM
5th Mar 20204:01 pmGNWGrant of Restricted Stock Units and PDMR Dealings
27th Feb 20207:00 amGNWVerona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
21st Feb 20207:00 amGNWVerona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
14th Feb 20207:00 amGNWVerona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
7th Feb 20207:00 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Feb 20207:00 amGNWVerona Pharma Announces Senior Management Changes
28th Jan 20207:00 amGNWVerona Pharma to Present at LSX World Congress 2020
17th Jan 20201:06 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 20205:00 amGNWVerona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.